Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
AcuCort AB (publ) ("AcuCort" or the "Company") announces today that one of its principal shareholders, the life science investor LSIF, has decided to exercise series TO 2 warrants ("TO 2") amounting to at least SEK 1 million, regardless of the current share price. The decision is being made public two days before the final exercise date, June 20, 2025, and highlights the confidence in AcuCort's continued commercial development.
"At LSIF, we have decided to support the subscription by subscribing for SEK 1 million regardless of the share price. Our motivation is that, in our view, the two LOIs - especially the one with Glenmark - are very strong signals that AcuCort is on track. We believe the current share price does not reflect the company's true potential."
- Jan Poulsen, CEO, LSIF
"We are very grateful for the continued confidence from LSIF and Jan Poulsen. Their investment provides us with additional resources to accelerate our commercial efforts. That Glenmark - a global pharmaceutical company with a strong presence in generics and specialty pharma - has not only signed a letter of intent with us but also approved its public disclosure, is a clear acknowledgment of the strategic value of Zeqmelit® and the significant market potential we see in Europe."
- Jonas Jönmark, CEO, AcuCort AB
By exercising TO 2, LSIF will subscribe for approximately 1.3 million new shares, thereby further strengthening its ownership in the Company.
Background: LOI with Glenmark and ongoing expansion
On June 17, 2025, AcuCort signed a letter of intent (LOI) with Glenmark Pharmaceuticals regarding the distribution and marketing of Zeqmelit® in six European countries, including Germany. These countries together have a population of over 160 million people and represent a central component of the Company's strategy to establish Zeqmelit® in several key European markets.
Summary of TO 2
Exercise period: June 9 - June 20, 2025 (final day for exercise: June 20, 2025)
Subscription price: SEK 0.75 per new share
Terms: One (1) TO 2 entitles the holder to subscribe for one (1) new share
Nominee-registered holders should follow the instructions from their bank/nominee, while directly registered holders must send a completed subscription form to Aqurat Fondkommission AB according to prior instructions.
Please note that any warrants not exercised by June 20, 2025, will expire without value.
For further information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Phone: +46 70 365 5400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-established corticosteroid dexamethasone. The drug is a smart product in an innovative, patented, and user-friendly administration form, primarily intended for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for COVID-19 patients requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on Spotlight Stock Market. Visit www.acucort.se.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is a research-driven, global pharmaceutical company operating in branded, generic, and over-the-counter products. The company has a particular focus on the therapeutic areas of respiratory, dermatology, and oncology. Glenmark operates four research and development centers, ten state-of-the-art manufacturing facilities across five continents, and has a presence in over 80 countries.